FDA scolds drugmaker for 'false or misleading'' claims

The FDA has reprimanded Dexcel and its affiliate Edenbridge Pharmaceuticals for "false or misleading" promotional claims regarding its brand-name drug Hemady. 

Related Posts

VCU hospital taps vice president of operations

Feb 14, 2025  0

UCHealth CFO's parting advice for his successor

Feb 24, 2025  0

FDA expands access for Schizophrenia treatment

Feb 26, 2025  0

Comments

Name

Email

Comment

Post Comment